These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26622860)

  • 1. Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.
    Shen J; Wang Q; Wang J; Su GH; Wang J; Guo SH; Liu YA; Wu Z; Liu RF; Li X; Guo XJ; Cao J; Zhang YH; Wang ZY
    Oncol Lett; 2015 Oct; 10(4):2403-2409. PubMed ID: 26622860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
    Jensen MK; Riisbro R; de Nully Brown P; Brünner N; Hasselbalch HC
    Eur J Haematol; 2002 Jul; 69(1):43-9. PubMed ID: 12270061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
    Guo H; Zhou LX; Ma H; Liu B; Cheng J; Ma YY; Zhao L
    Oncol Lett; 2017 Jul; 14(1):383-389. PubMed ID: 28693180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
    Mizukami IF; Todd RF
    J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
    Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
    Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
    Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
    Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
    Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
    Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.
    Piccolella M; Festuccia C; Millimaggi D; Locatelli A; Bologna M; Motta M; Dondi D
    Int J Oncol; 2008 Jan; 32(1):185-91. PubMed ID: 18097558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
    Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
    Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in patients with multiple myeloma].
    Luo LH; Xu GB; Lu XG
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Dec; 32(6):529-32. PubMed ID: 14712519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.